Quotes displayed are delayed by 15 minutes. Market data is provided by Telvent DTN
12 Mo. Price Change : 10% - ST has underperformed the S&P 500 by 15%

Get Trend Analysis Icon Get Trend Analysis

ETF Alternatives sponsored by

Ticker Name Weight % Change
No ETF alternatives available.


People viewing ST also viewed: , , , ,

Competitors

Ticker Name Volume % Change
SPAHD NOUVEAU HOLDINGS; LTD. 238.0 +4.44%
EQTL EQUITECH INTERNATIONAL 100.0 +1.48%
IMMCQ IMMUNICON 16.5K +1.00%
ESMC ESCALON MEDICAL 17.9K +0.34%
AERG APPLIED ENERGETICS 63.8K +0.28%

ST Stock Analysis

  1. Medtronic Still Reporting Weak Growth, But A Relatively Rare Bargain

    Medtronic continues to suffer with weak core markets, but business seems to be getting slowly better and valuation is not demanding
  2. ArcelorMittal Looks Like A Good House In A Really Tough Neighborhood

    ArcelorMittal looks too cheap, but it could be a long wait to see it really outperform
  3. Simpler Looks Better For First Horizon

    Deprioritizing non-strategic lending and refocusing on regional banking should be good for First Horizon in the long-term.
  4. Total Looks Cheap, But There's A Reason

    Total's performance looked pretty typical for the sector, but the company has a lot still to prove.
  5. Is Pepsi's Turnaround For Real?

    Pepsico (NYSE:PEP) announced first quarter earnings April 18. Better than expected, its stock jumped almost 3% on the news. The soda pop and snack food conglomerate is in the midst of a revitalization that's getting a lot of attention from investors. With its stock up 20% year-to-date, I question whether its good performance will continue.
  6. Broad Weakness Makes It Harder To Like St. Jude Today

    Although I do believe the long-term expectations for St. Jude are increasingly beatable, this could be a frustrating stock to own for a little while yet.
  7. Three Ways To Short Gold

    Investor enthusiasm for gold has been falling by the wayside. For portfolios, that could mean it's time to short the metal.
  8. Pharma Is Doing All The Pulling For Johnson & Johnson

    Although JNJ reported decent earnings and has some major new drugs lined up - downside risk is definitely still present.
Free Reports
  1. Get 4 quotes FREE - Refinance and Save

    Instant matching service with top lenders.
  2. Forbes Quant Model: 3 Top Stocks

    Using Forbes’ exclusive Quant Model, we’ve chosen three stocks that we think could double in price in the next 12 months.
  3. Find the Best Mortgage Rates

    Search and compare the best fixed and adjustable mortgage rates in your area with Bankrate.com.
Marketplace
Trading Center